贝伐珠单抗和信迪利单抗联合介入治疗对中晚期不可切除肝细胞癌疗效分析  

Analysis of efficacy of bevacizumab and sindilizumab combined with interventional therapy in the treatment of middle and advanced unresectable hepatocellular carcinoma

作　　者：王秀梅 周政荣 王向阳 WANG Xiumei;ZHOU Zhengrong;WANG Xiangyang(Department of Pharmacy,Zhoukou First People’s Hospital,Zhoukou 466000,China;Department of Oncology,Zhoukou First People’s Hospital,Zhoukou 466000,China)

机构地区：[1]周口市第一人民医院药学部,河南周口466000 [2]周口市第一人民医院肿瘤科,河南周口466000

出　　处：《肿瘤基础与临床》2025年第1期20-23,共4页journal of basic and clinical oncology

摘　　要：目的分析贝伐珠单抗和信迪利单抗联合介入治疗对中晚期不可切除肝细胞癌患者的治疗效果和安全性。方法选择2021年1月至2024年8月周口市第一人民医院肿瘤科收治的80例中晚期不可切除肝细胞癌患者,随机均分为贝伐珠单抗和信迪利单抗治疗的对照组,在对照组基础上联合介入治疗的观察组,每组40例。结果观察组疾病无进展生存期、完全缓解率、转手术率均优于对照组(χ^(2)=5.236,P=0.017;χ^(2)=4.020,P=0.045;χ^(2)=11.850,P<0.001)。结论贝伐珠单抗和信迪利单抗联合介入治疗具有更好的生存预后和转手术可能性,且安全性良好。Objective To analyze the therapeutic effect and safety of bevacizumab and sindilizumab combined with interventional therapy in the treatment of patients with middle and advanced unresectable hepatocellular carcinoma.Methods From January 2021 to August 2024,80 patients with middle and advanced unresectable hepatocellular carcinoma were admitted to the Department of Oncology of Zhoukou First People’s Hospital,which were divided into the control group treated with bevacizumab and sindilizumab,and the observation group treated with bevacizumab and sindilizumab combined with interventional therapy,with 40 patients in each group.Results The observation group exhibited significantly better outcomes in progression-free survival,complete response rate and surgical conversion rate compared to the control group(χ^(2)=5.236,P=0.017;χ^(2)=4.020,P=0.045;χ^(2)=11.850,P<0.001).Conclusion Bevacizumab and sindilizumab combined with interventional therapy demonstrates superior survival outcomes, enhanced likelihood of conversion to surgery, and an acceptable safety profile.

关 键 词：贝伐珠单抗 信迪利单抗 介入治疗 肝细胞癌 无进展生存期 

分 类 号：R735.7[医药卫生—肿瘤]